You are here: Industry Insights > Vaxart

News List

Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron AmericanPharmaceuticalReview
December 17, 2021
Vaxart, Inc. plans to test the cross-reactivity of its oral tablet COVID-19 vaccine candidate against the Omicron SARS-CoV-2 variant in two different studies expected to begin next month.
Vaxart Announces Acquisition of Second GMP Manufacturing Facility AmericanPharmaceuticalReview
December 02, 2021
Vaxart, Inc. has entered into an agreement with Kindred Bioscience, Inc. for the purchase of KindredBio’s manufacturing equipment and sublease of its GMP (Good Manufacturing Practices) manufacturing facility in Burlingame, California, giving Vaxart...
Vaxart Announces Creation of New Scientific and Clinical Advisory Board firstwordpharma
August 20, 2021
Vaxart, Inc. (NASDAQ: VXRT), today announced the creation of an eight-member Scientific and Clinical Advisory Board.
Vaxart and Altesa enter licencing deal for antiviral drug Vapendavir pharmaceutical-technology
July 09, 2021
Altesa Biosciences has entered an exclusive global licensing agreement with Vaxart to develop, produce and market the latter’s patented formulation of a clinical-stage antiviral drug, Vapendavir.
Vaxart’s Covid-19 vaccine shows cross-coronavirus activity in trial pharmaceutical-technology
May 06, 2021
Vaxart has reported the latest data from the Phase I trial of its first Covid-19 oral vaccine construct, VXA-CoV2-1, which showed broad cross-reactivity against other coronaviruses.
Vaxart’s oral vaccine candidate triggers immune response in Covid-19 trial pharmaceutical-technology
February 05, 2021
Vaxart has reported preliminary data from its Phase I study that showed its oral Covid-19 tablet vaccine candidate, VXA-CoV2-1, triggered multiple immune responses against SARS-CoV-2 antigens.
Vaxart Oral COVID-19 Vax Tablet Shows Promise contractpharma
February 04, 2021
Phase I study reached primary and secondary endpoints of safety and immunogenicity.
First patient dosed in COVID-19 vaccine tablet clinical trial europeanpharmaceuticalreview
October 16, 2020
A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate, has been initiated with the first patient dosed.
KindredBio Expands Manufacturing Agreement with Vaxart contractpharma
October 15, 2020
Centaur will manufacture Vaxart’s oral vaccine for COVID-19 and other vaccine candidates.
Kindred Bio Expands Agreement with Vaxart contractpharma
October 10, 2020
Centaur will manufacture Vaxart’s oral vaccine for COVID-19 and other vaccine candidates.

Previous page 1 2 Next page